由于太空突变发生的Ganoderma lucidum多糖的结构和功能益处
Bingqian Nie1, Jianle Chen2, Wenkang Wang1
1College of Biosystems Engineering and Food Science, National-Local Joint Engineering Laboratory of Intelligent Food Technology and Equipment, Zhejiang Key Laboratory for Agro-Food Processing, Zhejiang Engineering Laboratory of Food Technology and Equipment, Zhejiang University, Hangzhou 310058, China; College of Agriculture & Biotechnology, Zhejiang University, Hangzhou 310058, China.
Carbohydrate polymers
|May 18, 2025
概括
空间突变显著增强了Ganoderma lucidum多糖体,增加了产量并改变了结构,从而改善了抗炎作用. 这项研究突出了太空突变技术,用于开发先进的功能性食品.
科学领域:
- 药理学 药理学是指药理学的学科.
- 植物生物技术 植物生物技术
- 生物化学 生物化学
背景情况:
- (Ganoderma lucidum) 是一种药用,含有有价值的生物活性化合物.
- 太空突变育种是一种新兴的技术,用于增强植物特征.
研究的目的:
- 为了研究空间突变后Ganoderma lucidum多糖和类的结构和化学变化.
- 为了评估空间突变的Ganoderma lucidum的功能性质,特别是抗炎活性.
主要方法:
- 两步顺序提取 (热水和) 用于分离多糖.
- 液体染色学-质谱学 (LC-MS) 用于结构特征 (单糖化合物组成,甘油酸结合) 和化物分析.
- 对抗炎症活性的评估.
主要成果:
- 空间突变的Ganoderma lucidum显示出多糖产量 (178.59%至265.38%) 和类含量显著增加.
- 突变的多糖具有更高的葡萄糖含量,改变的单糖化合物组成,较低的分子量,以及富含β-1,3-葡萄糖的结构.
- 在空间突变的多糖体中观察到增强的抗炎活性.
结论:
- 空间突变诱导了Ganoderma lucidum多糖体的显著结构修饰,导致功能性质的增强.
- 这项研究提供了首次对Ganoderma lucidum polysaccharides中空间突变诱导的变化的全面分析.
- 太空突变技术为开发来自Ganoderma lucidum的新型功能性食品和药物提供了一个有前途的途径.
相关概念视频
Mismatch Repair
4.7K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.7K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K


